Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Oncotelic Therapeutics Inc
OTLCOncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. It develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company also develops OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. In addition, it is developing CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of support technologies. The company is headquartered in Agoura Hills, California. Address: 29397 Agoura Road, Agoura Hills, CA, United States, 91301
Analytics
Preço Alvo de Wall Street
4 USDRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave OTLC
Análise de Dividendos OTLC
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos OTLC
Avaliação de ações OTLC
Relatório OTLC
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |